智通财经APP讯，君圣泰医药-B(02511)公布，集团的全资附属公司深圳君圣泰生物技术有限公司与中国医学科学院医药生物技术研究所(药生所)共同开展课题合作，评估集团核心产品HTD1801对糖尿病伴慢性肾病(CKD with T2DM)的治疗潜力。该项目已于近日在中国医学科学院完成课题批准。基于本项目，双方将围绕糖尿病及伴慢性肾病适应症共同开展创新药物的机制和临床研究，致力于探索具备综合干预价值的创新治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.